25.06.2018 • News

Ineos Styrolution to add ABS line at Wingles

Ineos Styrolution to produce ABS at Wingles  (c) Ineos Styrolution
Ineos Styrolution to produce ABS at Wingles (c) Ineos Styrolution

Ineos Styrolution is investing an undisclosed sum to build a 50,000 t/y ABS plant at its Wingles, France, site. The company said it is reacting to increased demand for the polymer from the automotive, household, electronics, healthcare, construction and packaging industries in Europe. Up to now, it has not produced ABS at Wingles.

The Frankfurt, Germany, based subsidiary of the Swiss-headquartered olefins and polyolefins giant said the plant due to go on stream in the first quarter of 2020, will utilize the site’s  existing production infrastructure. One of the existing three PS lines will be converted into a to produce ABS.

Rob Buntinx, president of Ineos Styrolution for Europe, the Middle East and Africa (EMEA), said that having three ABS production sites in Europe –  apart from Wingles at Antwerp, Belgium, and Cologne, Germany – and a higher output production capacity will give the company more flexibility and allow it grow with its customers.

CEO Kevin McQuade said the plans for an upgrade of ABS capacity are part of the company’s focus on both standard grades and higher value specialties as outlined in its Triple Shift Strategy devised in 2013, when it was still a joint venture with BASF

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read